Unlike in NSCLC, where PD-L1 (programmed cell death ligand 1) serves as a reliable marker of the efficacy of immune checkpoint inhibitors, no correlation between the expression of this molecule on tumor cells and the efficacy of immunotherapy in small-cell lung cancer has been established. This evidence concerns the gene CD274 and neoplasm.